|
Name |
(1R,2S,12R,15R)-1-hydroxy-2,7-dimethoxy-12-(2-methylprop-1-enyl)-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-14,20-dione
|
| Molecular Formula | C23H27N3O5 | |
| IUPAC Name* |
(1R,2S,12R,15R)-1-hydroxy-2,7-dimethoxy-12-(2-methylprop-1-enyl)-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-14,20-dione
|
|
| SMILES |
CC(=C[C@@H]1C2=C([C@@H]([C@@]3(N1C(=O)[C@H]4CCCN4C3=O)O)OC)C5=C(N2)C=C(C=C5)OC)C
|
|
| InChI |
InChI=1S/C23H27N3O5/c1-12(2)10-17-19-18(14-8-7-13(30-3)11-15(14)24-19)20(31-4)23(29)22(28)25-9-5-6-16(25)21(27)26(17)23/h7-8,10-11,16-17,20,24,29H,5-6,9H2,1-4H3/t16-,17-,20+,23-/m1/s1
|
|
| InChIKey |
DARSEBUZHJPBHI-TVLQYADYSA-N
|
|
| Synonyms |
CYCLOTRYPROSTATIN B
|
|
| CAS | NA | |
| PubChem CID | 102379066 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 425.5 | ALogp: | 1.6 |
| HBD: | 2 | HBA: | 5 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 95.1 | Aromatic Rings: | 5 |
| Heavy Atoms: | 31 | QED Weighted: | 0.737 |
| Caco-2 Permeability: | -4.833 | MDCK Permeability: | 0.00000834 |
| Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.928 |
| Human Intestinal Absorption (HIA): | 0.213 | 20% Bioavailability (F20%): | 0.267 |
| 30% Bioavailability (F30%): | 0.986 |
| Blood-Brain-Barrier Penetration (BBB): | 0.105 | Plasma Protein Binding (PPB): | 75.54% |
| Volume Distribution (VD): | 1.276 | Fu: | 11.32% |
| CYP1A2-inhibitor: | 0.019 | CYP1A2-substrate: | 0.266 |
| CYP2C19-inhibitor: | 0.395 | CYP2C19-substrate: | 0.863 |
| CYP2C9-inhibitor: | 0.44 | CYP2C9-substrate: | 0.353 |
| CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.153 |
| CYP3A4-inhibitor: | 0.687 | CYP3A4-substrate: | 0.935 |
| Clearance (CL): | 5.71 | Half-life (T1/2): | 0.635 |
| hERG Blockers: | 0.038 | Human Hepatotoxicity (H-HT): | 0.98 |
| Drug-inuced Liver Injury (DILI): | 0.986 | AMES Toxicity: | 0.017 |
| Rat Oral Acute Toxicity: | 0.591 | Maximum Recommended Daily Dose: | 0.943 |
| Skin Sensitization: | 0.22 | Carcinogencity: | 0.181 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.94 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001958 | ![]() |
0.837 | D0J4JM | ![]() |
0.296 | ||
| ENC003264 | ![]() |
0.837 | D0G8NJ | ![]() |
0.293 | ||
| ENC002846 | ![]() |
0.740 | D06YFA | ![]() |
0.281 | ||
| ENC002064 | ![]() |
0.640 | D02IQY | ![]() |
0.258 | ||
| ENC002274 | ![]() |
0.618 | D01XNB | ![]() |
0.254 | ||
| ENC001060 | ![]() |
0.618 | D0C6DT | ![]() |
0.254 | ||
| ENC003013 | ![]() |
0.613 | D01TSI | ![]() |
0.251 | ||
| ENC000837 | ![]() |
0.596 | D09HDR | ![]() |
0.250 | ||
| ENC005479 | ![]() |
0.555 | D0P0RX | ![]() |
0.250 | ||
| ENC002042 | ![]() |
0.547 | D00XHD | ![]() |
0.244 | ||